




HepB3 / EPI suspension period: 6 months / vaccine impact: under 5-year-old children




EPI benefits versus COVID–19 risks

Hib3 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children




MCV1 / EPI suspension period: 6 months / vaccine impact: under 5-year-old children

MCV1 / EPI suspension period: 6 months / vaccine impact: under 5-year-old children



EPI benefits versus COVID–19 risks

PCV3 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



benefit–risk ratio



20


15

10

5

EPI benefits versus COVID–19 risks

RCV1 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children





10

5



EPI benefits versus COVID–19 risks

YFV / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



EPI benefits versus COVID–19 risks

MenA / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



EPI benefits versus COVID–19 risks

HPVfem / EPI suspension period: 6 months / vaccine impact: under 5–year–old children

